Respitide 25/125

Indonesia • Dexa Medica

Indication

Reversible obstructive airways disease (ROAD)
Respitide is indicated in the regular treatment of reversible obstructive airways disease (ROAD), including asthma in children and adults, where use of a combination (bronchodilator and inhaled corticosteroid) is appropriate. This may include:

  • Patients on effective maintenance doses of long-acting ß-agonist and inhaled corticosteroids
  • Patients who are symptomatic on current inhaled corticosteroid therapy
  • Patients on regular bronchodilator therapy who require inhaled corticosteroids

Chronic obstructive pulmonary disease (COPD)
Respitide is indicated for the regular treatment of chronic obstructive pulmonary disease (COPD) including chronic bronchitis and emphysema.

Composition

  • Salmeterol 25 mcg
  • Fluticasone 125 mcg

Package

1 canister of 120 doses

Dosage Forms

Inhalation Aerosol

ATC Classification

R03A

Warning

Alcohol
Consult Your Doctor
Safety of this item for use with alcohol has not been established. Please consult your doctor.
Machinery
Safe if Prescribed
This item is safe for use while operating heavy machinery.
Pregnancy
Caution
This item may not be safe for use during pregnancy. Use with caution and after consultation with your doctor.
Lactation
Not Recommended
This item is not safe for use during lactation.

Dosage

0 to 4 Years Old

There are no data available for use of salmeterol/fluticasone propionate in children aged under 4 years.

4 to 12 Years Old

Reversible obstructive airways disease (ROAD):
Two inhalations of 25 mcg salmeterol and 50 mcg fluticasone propionate twice daily.

12 to 18 Years Old

Reversible obstructive airways disease (ROAD):

  • Two inhalations of 25 mcg salmeterol and 50 mcg fluticasone propionate twice daily, or
  • Two inhalations of 25 mcg salmeterol and 125 mcg fluticasone propionate twice daily, or
  • Two inhalations of 25 mcg salmeterol and 250 mcg fluticasone propionate twice daily

18 to 65 Years Old

Reversible obstructive airways disease (ROAD):
Doubling the dose of all strengths of RESPITIDE in adults for up to 14 days has comparable safety and tolerability to regular twice daily dosing and may be considered when patients require additional short-term (up to 14 days) inhaled corticosteroid therapy as outlined in asthma treatment guidelines.

Chronic obstructive pulmonary disease (COPD):
For adult patients, the recommended dose is two inhalations 25/125 mcg to 25/250 mcg salmeterol/fluticasone propionate twice daily.

65 Years Old and Above

There is no need to adjust the dose.

Administration

Respitide inhaler is for inhalation only. Patients should be made aware that RESPITIDE Inhaler must be used regularly for optimum benefit, even when asymptomatic.

Patients with Hepatic Impairment

There is no need to adjust the dose.

Patients with Renal Impairment

There is no need to adjust the dose.

See All Products